Clinical trials
Locally Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting locally advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,366 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06623136RecruitingPhase 2
Testing a new combo for advanced lung cancer
This trial tests a new drug (ES102) combined with an immunotherapy (Toripalimab) for people with advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help those whose tumors have high PD-L1 levels.
Beijing, Beijing MunicipalityAges 18–75 - NCT06623461RecruitingPhase 2
Fecal transplant with immunotherapy for advanced melanoma
This trial tests if giving a special capsule of donated bacteria (fecal transplant) alongside standard immunotherapy helps shrink tumors in people with advanced melanoma. It aims to see if adding the bacteria can make the immune therapy work better.
Abbotsford British Columbia, British ColumbiaAges 18 years+ - NCT06632717RecruitingPhase 2
Chemo through liver artery with lipiodol for advanced liver cancer
This trial tests giving chemotherapy directly into the liver artery (HAIC) mixed with a special oil called lipiodol. It may help people with advanced liver cancer that cannot be treated with standard methods or who cannot tolerate them.
TaipeiAges 20 years+ - NCT06640283RecruitingPhase 2
Circulating tumor DNA monitoring for cervical and anal cancer
This trial uses a blood test to track tumor DNA in patients with HPV-related cervical or anal cancer. It aims to see if this test can detect early signs of recurrence after radiation therapy, helping guide follow-up care.
São PauloAges 18 years+ - NCT06648096RecruitingPhase 1/Phase 2
Testing afatinib for head and neck cancer in Fanconi anemia patients
This trial tests whether the targeted drug afatinib can shrink advanced head and neck cancers in people who also have Fanconi anemia. It is for patients whose tumors cannot be surgically removed and have not responded to or cannot have other standard treatments.
HanoverAges 18 years+ - NCT06650514RecruitingPhase 2
OMO-103 for advanced osteosarcoma
This trial tests a new drug called OMO-103, which targets a protein called Myc that helps cancer cells grow. It is for people with advanced osteosarcoma (bone cancer) that has worsened after standard chemotherapy. The drug is given intravenously (through a vein), and the study will check if it is safe and shrinks tumors.
BarcelonaAges 12 years+ - NCT06652048RecruitingPhase 2
High-dose Furmonertinib for advanced lung cancer after progression
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06659952Recruiting
HIV+ donor hearts for HIV+ recipients
This trial tests whether hearts from donors who had HIV can be safely transplanted into people with HIV who need a heart transplant. It may offer a new option for those on the waiting list.
Dallas, TexasAges 18 years+ - NCT06663319RecruitingPhase 1
Study of JNJ-89402638 for metastatic colorectal and gastric cancers
This trial tests a new drug, JNJ-89402638, alone or with other treatments for people with metastatic colorectal or gastric cancer that has progressed after standard therapies. It aims to find safe and effective doses and combinations.
Aurora, ColoradoAges 18 years+ - NCT06665178RecruitingPhase 2
Testing SG after T-DXd in ER+/HER2-low metastatic breast cancer
This trial tests whether a different chemotherapy drug, called sacituzumab govitecan (SG), can help people with ER+/HER2-low metastatic breast cancer who have already been treated with trastuzumab deruxtecan (T-DXd). It also looks at genetic markers in your tumor to predict who might benefit from SG.
Vancouver, British ColumbiaAges 18 years+ - NCT06668961RecruitingPhase 2
New combo therapy for head and neck cancer that has returned or spread
This trial is testing a combination of two targeted drugs (SI-B001 and SI-B003) plus chemotherapy as a first treatment for head and neck squamous cell carcinoma that has come back or spread to other parts of the body. The goal is to see if this combination works better than standard treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06678724Recruiting
Blood test study for head and neck cancer that has returned or spread
This trial is testing a new blood test (called a liquid biopsy) to better understand and predict the course of head and neck cancers that have come back or spread. If you join, researchers will use a special chip to look at your immune cells and tumor cells in your blood.
Zhubei, HsinChu CountyAges 20 years+ - NCT06684600RecruitingPhase 2
Treating advanced esophageal cancer with dalpiciclib and pyrotinib
This trial tests a combination of two targeted drugs (dalpiciclib and pyrotinib) for people with advanced esophageal squamous cell carcinoma whose cancer has gotten worse during or after first chemotherapy. The goal is to see if this drug pair can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT06690840RecruitingPhase 2
Atezolizumab plus chemo for advanced triple-negative breast cancer
This trial tests atezolizumab (an immunotherapy) plus chemotherapy to activate immune cells in people with triple-negative breast cancer that has spread or cannot be removed. It is for those who have had immunotherapy before during early treatment but not for advanced disease.
Monza, MonzaAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Prescott, ArizonaAges 18 years+ - NCT04634357RecruitingPhase 1/Phase 2
Testing donor-like immune T cells for children with liver cancer
This Phase 1/2 trial tests an immune-cell treatment (ET140203 T cells) in children and teens with certain liver cancers that have come back or did not respond to standard treatment. It aims to see whether these T cells can shrink tumors and is mainly focused on safety and early effectiveness.
Los Angeles, CaliforniaAges 1–21 - NCT07106034RecruitingPhase 2
Testing a new combo therapy for advanced colorectal cancer
This trial tests a combination of two drugs (ONGERICIMAB and TORIPALIMAB) for people with a specific type of colorectal cancer that did not respond to first treatment. It aims to see if this new approach can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06119581RecruitingPhase 3
Oloromosib with Immunotherapy as First Treatment for KRAS G12C Lung Cancer
This trial tests a new targeted pill (olomorasib) combined with immunotherapy (pembrolizumab) and possibly chemotherapy for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and has not been treated before.
Huntsville, AlabamaAges 18 years+ - NCT06881784RecruitingPhase 3
Study of a RAS-targeting pill for lung cancer
This trial tests a new daily pill (daraxonrasib/RMC-6236) for people with advanced non-small cell lung cancer that has a specific RAS mutation. It's for those who have already tried 1 or 2 previous treatments, including immunotherapy and chemotherapy.
Birmingham, AlabamaAges 18 years+ - NCT07136545RecruitingPhase 1/Phase 2
HCB101 plus pembrolizumab for advanced head and neck cancer
This trial tests a new drug, HCB101, combined with the immunotherapy pembrolizumab (Keytruda) for people with head and neck cancer that has come back or spread and is no longer responding to platinum chemotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth.
Taoyuan, Guishan DistrictAges 18 years+ - NCT07403136RecruitingPhase 2
Testing Becotatug Vedotin ± Immunotherapy for advanced esophageal cancer
This trial tests a new targeted drug (Becotatug Vedotin) given either alone or with an immunotherapy drug for people with advanced esophageal squamous cell cancer that has EGFR protein on their tumor cells. The goal is to see if this combination can help when standard treatments have stopped working.
ShanghaiAges 18 years+ - NCT06915025RecruitingPhase 3
Study of a new drug for advanced ovarian cancer
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
Orlando, FloridaAges 18 years+ - NCT06709495RecruitingPhase 1/Phase 2
PEEL-224 with chemo for teens and young adults with sarcoma
This trial tests a new drug called PEEL-224 combined with two chemotherapy drugs (vincristine and temozolomide) for people ages 12 to 49 with sarcoma that has come back or hasn't responded to standard treatments. The goal is to see if this combination is safe and effective.
Boston, MassachusettsAges 12–49 - NCT06717243Recruiting
Study on gene markers in lung cancer for treatment resistance
This study looks at genetic markers in two types of lung cancer (small cell and large cell neuroendocrine) to understand why some tumors stop responding to a standard treatment that combines chemotherapy with immunotherapy. If you have one of these cancers and are about to start this treatment, you may be able to join.
New York, New YorkAges 18–85
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 3,366 recruiting locally advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.